Medigene gambles on dendritic cell cancer vaccines in Trianta buyout

John Carroll

Germany's AG has nabbed a small vaccine developer in a which will add a team of investigators from one of the country's top research institutes. Medigene agreed to pay about 4 million euros in stock for Immunotherapies, with another 6 million euro chunk held aside for possible milestone payments.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS